Bausch Health presents 1,630-patient liver disease study at AASLD 2026
Salix reports 62% one-year survival and high rehospitalisation in severe alcohol-associated hepatitis, highlighting gaps in long-term care.
Pharma & Biotech
Pharma & Biotech
RED-C setback for Bausch Health: What this failed Phase 3 trial reveals about cirrhosis care gaps
Bausch’s RED-C trial failed to meet endpoints in hepatic encephalopathy prevention. Find out what this means for rifaximin SSD’s future and the field.